CASE PRESENTATION
- 77-year-old female with glaucoma OS
- New referral
- Intolerant to all drops, including preservative free
BASELINES
ASSESSMENT
- SLT was performed: IOP 26 mm Hg
- IOP too high for optic nerve
TREATMENT DECISION
XEN® Gel Stent implantation OS.
XEN® Gel Stent Post-op Outcomes
CONCLUSION
- IOP was successfully lowered OS with XEN® Gel Stent in pseudophakic
patient intolerant to all drops, including preservative free - IOP maintained at 13 mm Hg on no IOP-lowering medications
To learn more about identifying patients who could benefit
from XEN® Gel Stent, contact your Allergan representative.
IOP = intraocular pressure; LASIK = laser-assisted in situ keratomileusis; MTMT = maximum tolerated medical therapy; OCT = optical coherence tomography;
PCIOL = posterior chamber intraocular lens; RNFL = retinal nerve fiber layer; SLT = selective laser trabeculoplasty.
CASE PRESENTATION
- 85-year-old Hispanic female
- Cataract extraction OU 8 years ago
- History of moderate glaucoma
- Unable to tolerate a majority of topical IOP-lowering medications
BASELINES
ASSESSMENT
- Unable to tolerate all classes of IOP-lowering medication except PGA
– On PGA OU QHS, there has been progressive loss of RNFL and GCA
TREATMENT DECISION
XEN® Gel Stent implantation OD, followed by OS.
XEN® Gel Stent Post-op Outcomes
CONCLUSION
- XEN® Gel Stent reduced IOP OU through year 2, with 1 IOP-lowering medication OD
To learn more about identifying patients who could benefit
from XEN® Gel Stent, contact your Allergan representative.
GCA = ganglion cell arteritis; IOP = intraocular pressure; MTMT = maximum tolerated medical therapy; OCT = ocular coherence tomography;
PGA = prostaglandin analog; QHS = every night at bedtime; RNFL = retinal nerve fiber layer.